FDA Bests Annual Novel Drug Approval Record With Four Oks In One Week
Executive Summary
The agency's Dec. 21 approval of Giapreza became novel drug No. 46 of 2017, topping the 2015 mark of 45.
You may also be interested in...
Keeping Track: A Glut Of Big Approvals While Lartruvo Makes Its Market Exit
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Thumbs Up For Abbvie and GSK; Thumbs Down For Insys
The latest drug development news and highlights from our US FDA Performance Tracker.
CNS Treatments Highlight US FDA's Busy Pipeline Of Novel Agents For 2018
Rare disease and infectious disease candidates also are among the most common treatments in agency's review queue.